AUS
NZ
UK
CA
USA
IND
_07_03_2026_03_50_21_133108.jpg)
On 28 July 2026, Radiopharm Theranostics Limited (ASX:RAD) completed the issuance of 384,493,800 fully paid ordinary shares under the relief provisions of section 708A(5)(e) of the Corporations Act 2001. This issuance was conducted without the need for disclosure under Part 6D.2 of the Corporations Act, marking the conclusion of a capital management transaction. The company’s notice confirms full compliance with relevant regulatory requirements at the time of the share issue.
Key Highlights
- Radiopharm Theranostics Limited (ASX:RAD) issued 384,493,800 fully paid ordinary shares on 28 July 2026.
- Shares were issued under section 708A(5)(e) relief, exempting disclosure obligations under Part 6D.2 of the Corporations Act.
- Company confirms compliance with chapter 2M and sections 674 and 674A of the Corporations Act as of the notice date.
- No excluded information was identified as per sections 708A(7) and 708A(8) at the time of issuance.
Details of Radiopharm Theranostics’ Share Issuance and Regulatory Compliance
Radiopharm Theranostics Limited, trading on the ASX under the ticker RAD, finalized a major share placement involving 384,493,800 ordinary fully paid shares on 28 July 2026. The issuance was formally notified under section 708A(5)(e) of the Corporations Act 2001 (Cth), which allows companies to issue shares without a prospectus or extensive disclosure documentation under certain conditions.
This regulatory relief facilitates capital transactions by exempting companies from disclosure obligations when specific criteria are met. By leveraging section 708A(5)(e), Radiopharm Theranostics efficiently completed its share placement while adhering to Australian financial services regulations. The company’s notice affirms that all regulatory requirements were satisfied at issuance, providing assurance to investors and market participants.
Regulatory Compliance Status at Issuance Date
At the date of the notice, Radiopharm Theranostics confirmed compliance with chapter 2M of the Corporations Act, which governs corporate governance, director responsibilities, and other foundational obligations for Australian public companies. This confirmation indicates that the company’s governance and officer duties were fully compliant at the time.
Additionally, compliance with sections 674 and 674A was affirmed. Section 674 relates to the issuance of securities without disclosure, while section 674A covers continuous disclosure obligations. The company’s confirmation that no excluded information existed under sections 708A(7) and 708A(8) means there was no material information that needed to be disclosed to invalidate reliance on the relief provisions.
Implications of the 384.5 Million Share Placement on Capital Structure
The issuance of 384,493,800 ordinary shares represents a significant increase in Radiopharm Theranostics’ issued capital. This sizeable placement likely supports strategic or financial objectives, with the prompt notice issuance on 28 July 2026 reflecting the company’s commitment to timely disclosure. Investors should consider potential dilution effects on earnings per share and ownership percentages.
The statutory notice does not disclose the subscription price, allocation details, or whether the placement was at a discount or premium to market price. Such notices typically serve as compliance confirmations rather than detailed investment documents.
Excluded Information and Investor Disclosure Considerations
Radiopharm Theranostics’ statement confirming no excluded information under sections 708A(7) and 708A(8) is crucial. Excluded information refers to material facts that a reasonable investor would consider important when deciding to acquire securities. The absence of such information indicates no undisclosed material developments existed at the time of issuance, supporting market integrity and investor protection.
This confirmation ensures no unfair information advantage existed between existing shareholders and new investors participating in the placement. However, it applies only as of the issuance date and does not cover subsequent developments.
Company Operations and Sector Overview
Radiopharm Theranostics operates in the radiopharmaceuticals sector, specializing in the development and commercialization of radioactive diagnostic and therapeutic products. Based in Carlton South, Victoria, Australia, the company is ASX-listed and subject to stringent regulatory and governance standards. The sector demands significant capital for R&D, clinical trials, manufacturing scale-up, and commercialization efforts.
The scale of this capital raise suggests Radiopharm Theranostics is advancing a significant growth or development phase, possibly funding clinical trials, manufacturing capabilities, or commercial milestones. The radiopharmaceuticals market has experienced growing investment due to rising demand for precision medicine and diagnostic imaging.
Section 708A(5)(e) Relief and Market Practices
Section 708A(5)(e) of the Corporations Act allows listed entities to issue securities without disclosure under Part 6D.2, provided certain conditions are met. This relief supports capital management by established ASX-listed companies with strong disclosure records and no excluded information. Companies must confirm compliance via market notices, as Radiopharm Theranostics has done.
This mechanism is commonly used for capital raises, employee share schemes, and corporate transactions, balancing capital flexibility and investor protection through ongoing disclosure obligations.
Ongoing Governance and Disclosure Obligations Post-Issuance
By confirming compliance with chapter 2M and sections 674 and 674A, Radiopharm Theranostics acknowledges its continuing obligations as an ASX-listed entity. These include continuous disclosure, financial reporting, shareholder meetings, and maintaining governance standards. The confirmation supports reliance on relief provisions but does not suspend ongoing disclosure duties.
The company must continue disclosing material information affecting its financial condition or operations in line with ASX rules. Investors should monitor future announcements and financial reports to assess the impact of the capital raise.
Investor Considerations Following the Capital Raise
Post-placement, investors should watch for updates on the deployment of the raised capital, including clinical development, manufacturing expansion, working capital use, or debt reduction. Operational milestones such as clinical trial outcomes, regulatory approvals, or partnerships will indicate progress toward strategic goals. Changes in earnings per share or capital structure may also reflect the placement’s effects.
The company has not disclosed the capital raise’s purpose, subscription price, or proceeds usage in this notice; such details may appear in other announcements or financial reports. Investors are encouraged to review Radiopharm Theranostics’ full disclosure record to understand the strategic context and capital application. Continuous disclosure obligations ensure material information will be communicated timely.
